WASHINGTON— Federal health regulators have approved an attention deficit disorder drug for a new use: A first-of-its kind treatment for binge-eating disorder. About 2 percent of U.S. adults, or about 5 million people, have binge eating disorder, according to the Department of Health and Human Services. The Food and Drug Administration originally approved...» Read More
An experimental GlaxoSmithKline drug, designed to fight heart disease in a new way, failed to meet its main goal in a major clinical study.
London-listed Shire has agreed to buy U.S. company ViroPharma for about $4.2 billion in cash.
The FDA proposed a new rule that would open up generic drugmakers to liability and apply some of the same regulations used for brand manufacturers.
CNBC's Tyler Mathisen, Jon Fortt and Michelle Caruso-Cabrera debate the money to be made from the legalization of marijuana.
You've heard of ED. Now there's a drug for PE, made by a 4-year-old start-up. It's designed for men to make their mates happier.
Will.i.am talks to CNBC about the "failure" of the Drug Abuse Resistance Education program and how thousands of Americans are now in prison because of lack of opportunities in their neighborhood.
The FDA is expected to decide on whether to fast track Perjeta for early treatment of breast cancer by Oct. 31.
Biogen Idec has agreed to pay another $100 million upfront to Isis Pharmaceuticals as part of a broad collaboration to develop neurological medicines.
The cannabis legalization trend is creating jobs in states where laws have been relaxed, and big business is "looking into the industry in a big way," an expert says.
A warning about stock scams involving marijuana related companies has been issued; CNBC's Mary Thompson has the story.
FINRA is issuing a new investor alert called "marijuana stock scams." CNBC's Mary Thompson offers insight.
FINRA warned Tuesday that scammers have been targeting investors attempting to tap into the growing U.S. marijuana industry.
Colorado and Washington are trying to figure out a system to regulate and track the use of legalized marijuana, reports CNBC's Jane Wells.
Doug Fine, author of 'Too High to Fail', explains the benefits to the economy that legalizing cannabis in the U.S. would have.
CNBC's Tom Mackenzie comments on the need for a globally coordinated approach to tackling the drugs trade.
Steve Sampson, author of Narcomania: How Britain got hooked on drugs, tells CNBC that self-contradiction defines British drug policy.
Vanda Felbab-Brown, senior fellow at the Brookings Institute, tells CNBC that the drug trade is becoming more global with demand coming out of the emerging markets.
A growing epidemic of overdoses of prescription painkillers is leading to record numbers of deaths, especially among women, the Centers for Disease Control and Prevention says.
Life after the NFL is tough for players when they retire. A look at a few and their involvement in the tech industry, with Atlanta Falcons tight end Tony Gonzalez, of FitStar, and former NFL player Tony Mandarich, of the Mandarich Media Group.
China is barring a GlaxoSmithKline executive from leaving the country amid a widening $490 bribery scandal ensaring the drug giant.